LONDON, - British drugmaker GSK will no longer set diversity targets, it said on Thursday, as it became the latest company to scale back or abandon such goals in response to the U.S. president's ...
You can find him on X @AlexOnRacing. Cody Ware faced a challenging day at the "frustrating" Daytona last weekend. Despite strong efforts, Ware and his team couldn't avoid getting caught up in a ...
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. UK drugmaker GSK is struggling to convince the market that it can deliver on its plans to refill its ...
Authorities rescued a Ware man on Feb. 12, nearly 22 hours after he was reported missing, by tracking his footprints in the snow through woods near the Quabbin Reservoir, where he was found ...
Bernstein analyst Florent Cespedes maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £22.90. The company’s shares opened today at p1,443. ...
The shares of GlaxoSmithKline Pharmaceuticals Ltd (GSK Pharma) jumped over 15 percent to trade at Rs 2,684 apiece on February 18, extending gains for the second straight session after releasing ...
GlaxoSmithKline share price jumped more than 17% on Tuesday and extended its surge for the third consecutive session. GlaxoSmithKline shares spiked as much as 17.69% to ₹2,744.95 apiece on the ...
GSK's revenue and EPS exceeded my expectations and those of analysts, thanks to the strong performance of its oncology and HIV franchises. So, Ojjaara/Omjjara sales amounted to $150 million in the ...
The Food and Drug Administration on Friday gave a green light to a new meningococcal vaccine from GSK. Dubbed Penmenvy, the “5-in-1” shot is approved for people aged 10 through 25 years old and ...
Shares of GlaxoSmithKline Pharmaceuticals Ltd. are trading with gains of 20% on Monday, February 17, bucking in trend in a market where most Nifty 50 constituents are trading with losses. GSK Pharma ...
GlaxoSmithKline Pharmaceuticals shares hit 20 per cent upper circuit in trade on BSE at Rs 2,421.3 per share. The buying on the counter came after the company posted its Q3 results. Around 9:52 AM, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results